Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Forest hopes the SNRI can follow the enantiomer blockbuster model. The application includes in vitro data showing that levomilnacipran has a greater potency for norepinephrine reuptake inhibition, without directly affecting the uptake of dopamine or other neurotransmitters.

You may also be interested in...



APA Update: New Antidepressants Elbow Into Crowded Market

Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.

MDD Market Snapshot: Depressing Future For Antidepressants

Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.

Forest Buys Clinical Data And Extends Its Antidepressant Portfolio

The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS004959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel